Key Takeaways
- • OrbiMed has raised $3bn across its latest US and European life sciences fund and its sixth Asian healthcare investment vehicle, according to AltAssets.
- • The Asian healthcare vehicle surpassed $1bn in commitments for the first time, reflecting the manager's expanding exposure to the region's biotechnology industry.
- • The raise spans multiple new healthcare vehicles, signaling continued institutional demand for specialist life sciences capital.
Summary
OrbiMed has raised $3bn across its latest US and European life sciences fund and its sixth Asian healthcare investment vehicle, according to a publisher summary from AltAssets. The headline figure combines capital raised across the new healthcare funds, with the Asian vehicle reaching more than $1bn for the first time in the manager's history.
The milestone for the Asian vehicle underscores OrbiMed's deepening commitment to the region's biotechnology sector. The sixth Asian healthcare vehicle's crossing of the $1bn threshold indicates sustained allocator interest in healthcare exposure across Asia as the manager expands its footprint there.
The full article is behind a premium paywall, so this summary relies on the publisher's summary and headline. Specific fund names, individual commitment amounts for each vehicle, and investor breakdowns were not available in the accessible text.
The milestone for the Asian vehicle underscores OrbiMed's deepening commitment to the region's biotechnology sector. The sixth Asian healthcare vehicle's crossing of the $1bn threshold indicates sustained allocator interest in healthcare exposure across Asia as the manager expands its footprint there.
The full article is behind a premium paywall, so this summary relies on the publisher's summary and headline. Specific fund names, individual commitment amounts for each vehicle, and investor breakdowns were not available in the accessible text.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.